StockData
Stryker Corp logo

Stryker Corp (SYK) stock

SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3024% below fair value
$291.86−19.89 (-6.38%)

Close on Oct 30, 2026Market cap $111.95BP/E 31.1Yield –

Earnings

Stryker's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 28, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$6.50B
+6.6% on a year earlier
adjusted net earnings per diluted share, Q3 FY2026
$3.52
$3.19 a year earlier
Latest guidance
Issued
Oct 29, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Stryker's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Jan 28, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026after the close$6.50B+6.6%$1.96$3.52Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close$6.60B+10.0%$3.30$3.69Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026after the close$6.00B+1.7%$1.93$2.60Release
Q4 FY2025ended Dec 31, 2025Jan 29, 2026after the close$7.20B+12.5%$2.20$4.47Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025after the close$6.10B+10.9%$2.22$3.19Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025after the close$6.00B+11.1%$2.29$3.13Release
Q1 FY2025ended Mar 31, 2025May 1, 2025after the close$5.90B+13.5%$1.69$2.84Release
Q4 FY2024ended Dec 31, 2024Jan 28, 2025after the close$6.40B+10.3%$1.41$4.01Release
Q3 FY2024ended Sep 30, 2024Oct 29, 2024after the close$5.50B+12.2%$2.16$2.87Release
Q2 FY2024ended Jun 30, 2024Jul 30, 2024after the close$5.40B+8.0%$2.14$2.81Release
Q1 FY2024ended Mar 31, 2024Apr 30, 2024after the close$5.20B+8.3%$2.05$2.50Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Stryker's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
organic net sales growthnon-GAAPFY2026+6.5% – +7%–NewOct 29, 2026
organic net sales growth (2)non-GAAPFY2026+8% – +9.5%+8% – +9.5%ReaffirmedApr 30, 2026
organic net sales growthnon-GAAPFY2026+8.3% – +9.3%–NewJul 30, 2026
adjusted net earnings per diluted sharenon-GAAPFY2026$14.80 – $14.90–NewOct 29, 2026
adjusted net earnings per diluted sharenon-GAAPFY2026$14.95 – $15.10$14.90 – $15.10RaisedJul 30, 2026

Guidance vs results

The last range Stryker gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025adjusted net earnings per diluted share$13.50 – $13.60$13.63Σ4QAbove range

Guidance history

Every forecast Stryker put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026adjusted net earnings per diluted shareFY2026$14.80 – $14.90New
Oct 29, 2026organic net sales growthFY2026+6.5% – +7%New
Jul 30, 2026organic net sales growthFY2026+8.3% – +9.3%New
Jul 30, 2026adjusted net earnings per diluted shareFY2026$14.95 – $15.10Raised
Apr 30, 2026adjusted net earnings per diluted share (2)FY2026$14.90 – $15.10Reaffirmed
Apr 30, 2026organic net sales growth (2)FY2026+8% – +9.5%Reaffirmed
Jan 29, 2026adjusted net earnings per diluted shareFY2026$14.90 – $15.10New
Jan 29, 2026organic net sales growthFY2026+8% – +9.5%New
Oct 30, 2025adjusted net earnings per diluted shareFY2025$13.50 – $13.60Raised
Oct 30, 2025organic net sales growthFY2025+9.8% – +10.2%Raised
Jul 31, 2025adjusted net earnings per diluted shareFY2025$13.40 – $13.60New
Jul 31, 2025organic net sales growthFY2025+9.5% – +10%New
May 1, 2025adjusted net earnings per diluted shareFY2025$13.20 – $13.45Lowered
May 1, 2025organic net sales growthFY2025+8.5% – +9.5%Raised
Jan 28, 2025adjusted net earnings per diluted share (2)FY2025$13.45 – $13.70New
Jan 28, 2025organic net sales growth (2)FY2025+8% – +9%New
Jan 28, 2025sales in the 2025 stub period on a constant currency basisFY2025$590.00MNew
Oct 29, 2024adjusted net earnings per diluted shareFY2024$12.00 – $12.10Raised
Oct 29, 2024favorable pricing impactFY20240.5% – 1%New
Oct 29, 2024adjusted net earnings per diluted share impact from foreign exchange ratesFY2024-$0.10New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Stryker filed with the SEC as exhibits to Form 8-K or 6-K

  1. STRYKER REPORTS THIRD QUARTER 2026 OPERATING RESULTS
    Results
  2. Kevin Lobo to transition to Executive Chair of the Board of Directors
    Update
  3. Kevin Lobo Strengthened Stryker as a diversified global leader in medical technologies 14 years of transformative leadership Legacy of
    Update
  4. Spencer Stiles President and Chief Operating Officer Incoming Chief Executive Officer | Effective January 1, 2027 I am honored to
    Update
  5. STRYKER REPORTS SECOND QUARTER 2026 OPERATING RESULTS
    Results
  6. Management’s Discussion and Analysis of Financial Condition and Results of Operations
    News
  7. STRYKER REPORTS FIRST QUARTER 2026 OPERATING RESULTS
    Results
  8. David Nathans, Vice President, Chief Information Security Officer
    Update
  9. Customer Update: Stryker Network Disruption
    Update
  10. STRYKER REPORTS 2025 OPERATING RESULTS AND 2026 OUTLOOK
    Results
  11. Stryker names Spencer Stiles President and Chief Operating Officer
    Update
  12. STRYKER REPORTS THIRD QUARTER 2025 OPERATING RESULTS
    Results
  13. STRYKER REPORTS SECOND QUARTER 2025 OPERATING RESULTS
    Results
  14. STRYKER REPORTS FIRST QUARTER 2025 OPERATING RESULTS
    Results
  15. Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President,
    Update